Developer docs
API playgroundTry for free, no card

Search company profiles

PicturaBio

Full company profile

uuid0058qch

Namestring
PicturaBio
Legal namestring
Pictura Bio Ltd
Websiteurl
pictura.bio
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, infectious disease detection, pathogen identification, AI-powered diagnostics, molecular imaging devices
Industry2 codes
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Infectious Disease Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Device Sales
TypeHardware Sales
Description

Sale of VISTA Reader hardware and single-use test cartridges to healthcare facilities including hospitals, GP surgeries, pharmacies, and point-of-care settings.

pictura.bio
2Software Updates and Licensing
TypeLicensing Royalties
Description

Revenue from software updates that train the AI to recognize new pathogens. New tests distributed via software update to already deployed systems, enabling continuous platform expansion.

pictura.bio
3Government and Defence Contracts
TypeProfessional Services
Description

Revenue from contracts with UK Ministry of Defence and DASA for ruggedized diagnostic systems designed for front-line military and field use environments.

pictura.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1PIC-ID
Description

Proprietary universal labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. The core patented technology platform.

pictura.bio
+4 more records
Core offering1 text field

Pictura Bio develops and is commercialising a one-minute infectious disease pathogen detection platform combining a proprietary universal fluorescent labelling reagent (PIC-ID Capture), a benchtop fluorescence microscopy instrument (VISTA Reader), and a deep learning image analysis algorithm (PIC-ID Identify). The integrated platform is sold to hospitals, GP surgeries, pharmacies, and defence customers for point-of-care identification of respiratory viruses, bacteria, and other pathogens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 97-98% accuracy from 155 patient samples in clinical validation
+5 more records
Product overview1 text field

PicturaBio offers the world's first one-minute pathogen recognition platform called PIC-ID. The platform comprises three integrated components: PIC-ID Capture (universal fluorescent labeling reagent), VISTA Reader (specialized benchtop fluorescent microscopy instrument), and PIC-ID Identify (deep learning image analysis software). The system works by tagging pathogens with a single universal reagent, capturing their unique fluorescent signatures via microscopy, and using machine learning algorithms to identify and differentiate between multiple pathogens simultaneously. A military variant called IDRIS provides ruggedized field deployment capability. The company is developing VISTA Alpha (near market-ready system expected July 2026) and VISTA Beta (clinical trials-ready system expected July 2026).

Product and service3 records
1PIC-ID Platform (Pathogen Identification and Classification)
CategoryInfectious Disease Diagnostics Platform
Description

Integrated diagnostic platform combining a proprietary universal fluorescent labelling reagent, a benchtop fluorescence microscopy instrument, and a deep learning image analysis algorithm to deliver one-minute pathogen identification at the point of care. Sold to NHS hospitals, GP surgeries, pharmacies, and defence customers.

2IDRIS (In-Field Diagnostic for Rapid Infection Sensing)
CategoryMilitary / Field Diagnostics Hardware
Description

Ruggedised, portable diagnostic device for military frontline point-of-care infectious disease detection, built on the patented PIC-ID fluorescent labelling and machine learning platform. Delivers results in under 5 minutes with 99% accuracy from throat and nose swab samples. Sold to UK Ministry of Defence and allied military forces.

3PIC-ID Capture (consumable reagent cartridges)
CategoryDiagnostic Reagents / Consumables
Description

Proprietary single universal fluorescent labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. One reagent serves all tests, simplifying inventory versus pathogen-specific primers. Sold as a consumable alongside the VISTA Reader.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with NHS Portsmouth Emergency Department for clinical validation of the Pictura Bio diagnostic platform. Company explicitly mentions this partnership as fundamental to overcoming clinical adoption challenges.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partner for Novel Technologies for Respiratory Virus Identification (ResVir) study registered as NCT05661032. First large-scale sample collection initiative generating respiratory pathogen dataset for PIC-ID Identify machine learning training.

3John Radcliffe Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated with John Radcliffe Hospital to evaluate the diagnostic method using AI software to identify viruses. Over 200 clinical samples were labelled and analysed, demonstrating >97% accuracy in identifying respiratory viruses.

pictura.bio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pictura Bio is a spinout from the University of Oxford. Scientific co-founders Nicolas Shiaelis and Dr. Nicole Robb originated from Oxford. Company maintains connection with Oxford's emerging viruses research group led by Professor Miles Carroll.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

QuantuMDx is a UK-based developer of the Q-POC rapid molecular POC platform. As a similarly-sized UK diagnostics challenger targeting decentralized infectious disease and antimicrobial resistance testing, it is closely comparable in stage and go-to-market motion.

TypeDirect peer
Description

Qiagen's QIAstat-Dx is a syndromic molecular diagnostic platform for respiratory and gastrointestinal infections, directly comparable to PicturaBio's multiplex POC positioning. Both target hospital labs and EDs with rapid, panel-based detection.

TypeDirect peer
Description

bioMérieux's BioFire FilmArray is the dominant multiplex syndromic molecular panel for rapid infectious disease diagnostics in hospitals, targeting the same ED/ICU customer segment as PicturaBio's VISTA. Both platforms deliver rapid, sample-to-answer multiplex pathogen identification from a single sample.

TypeDirect peer
Description

Cepheid's GeneXpert is the market-leading rapid molecular point-of-care platform for infectious disease (TB, CT/NG, respiratory viruses, SARS-CoV-2). It competes head-to-head with PicturaBio on turnaround time and decentralization for hospitals and clinics.

TypeDirect peer
Description

T2 Biosystems uses T2 Magnetic Resonance to detect pathogens (T2Candida, T2Bacteria) directly from whole blood without culture. It is a direct peer in rapid, culture-independent pathogen identification at the hospital bedside.

TypeEmerging player
Description

Accelerate Diagnostics' Pheno system provides rapid ID and AST directly from positive blood cultures. It competes in the same rapid-pathogen-identification workflow that PicturaBio's universal-labelling / AI approach ultimately aims to address.

TypeBroad incumbent
Description

Bruker's MALDI Biotyper is a widely deployed rapid microbial identification platform using mass spectrometry in clinical microbiology labs. As a broad incumbent in microbial ID, it competes for the same hospital-lab budget that PicturaBio's VISTA targets.

TypeDirect peer
Description

Binx Health's io system is a rapid molecular POC platform initially deployed for CT/NG testing at pharmacies, clinics and EDs - directly comparable in targeting decentralized clinical settings with rapid sample-to-answer molecular diagnostics.

TypeEmerging player
Description

Specific Diagnostics develops a rapid phenotypic ID/AST platform using biochemical sensors, targeting bloodstream infection identification and antibiotic susceptibility within hours. It is an emerging peer in the rapid phenotypic pathogen identification space where PicturaBio also competes.

TypeEmerging player
Description

Oxford Nanopore's sequencing-based platform is being adopted for rapid infectious disease surveillance and outbreak response. It is an adjacent, emerging technology converging on rapid decentralized pathogen identification - though via sequencing rather than imaging/AI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PicturaBio

Infectious Disease Diagnosticspictura.bio

PicturaBio firmographics

Firmographics
Name
PicturaBio
Legal name
Pictura Bio Ltd
Website
https://pictura.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

PicturaBio industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Point-of-care diagnostics
  • Infectious disease detection
  • Pathogen identification
  • AI-powered diagnostics
  • Molecular imaging devices

Where PicturaBio is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

PicturaBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Device Sales: Sale of VISTA Reader hardware and single-use test cartridges to healthcare facilities including hospitals, GP surgeries, pharmacies, and point-of-care settings.
  2. Software Updates and Licensing: Revenue from software updates that train the AI to recognize new pathogens. New tests distributed via software update to already deployed systems, enabling continuous platform expansion.
  3. Government and Defence Contracts: Revenue from contracts with UK Ministry of Defence and DASA for ruggedized diagnostic systems designed for front-line military and field use environments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

PicturaBio product offering

Product offering

Core offering

Pictura Bio develops and is commercialising a one-minute infectious disease pathogen detection platform combining a proprietary universal fluorescent labelling reagent (PIC-ID Capture), a benchtop fluorescence microscopy instrument (VISTA Reader), and a deep learning image analysis algorithm (PIC-ID Identify). The integrated platform is sold to hospitals, GP surgeries, pharmacies, and defence customers for point-of-care identification of respiratory viruses, bacteria, and other pathogens.

Product overview

PicturaBio offers the world's first one-minute pathogen recognition platform called PIC-ID. The platform comprises three integrated components: PIC-ID Capture (universal fluorescent labeling reagent), VISTA Reader (specialized benchtop fluorescent microscopy instrument), and PIC-ID Identify (deep learning image analysis software). The system works by tagging pathogens with a single universal reagent, capturing their unique fluorescent signatures via microscopy, and using machine learning algorithms to identify and differentiate between multiple pathogens simultaneously. A military variant called IDRIS provides ruggedized field deployment capability. The company is developing VISTA Alpha (near market-ready system expected July 2026) and VISTA Beta (clinical trials-ready system expected July 2026).

Differentiator

Problem solved

Functional benefit

Brands

  • PIC-ID: Proprietary universal labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. The core patented technology platform.
  • VISTA Reader
  • PIC-ID Identify
  • IDRIS
  • IRIS

Products and services

  • PIC-ID Platform (Pathogen Identification and Classification) Integrated diagnostic platform combining a proprietary universal fluorescent labelling reagent, a benchtop fluorescence microscopy instrument, and a deep learning image analysis algorithm to deliver one-minute pathogen identification at the point of care. Sold to NHS hospitals, GP surgeries, pharmacies, and defence customers.
  • IDRIS (In-Field Diagnostic for Rapid Infection Sensing) Ruggedised, portable diagnostic device for military frontline point-of-care infectious disease detection, built on the patented PIC-ID fluorescent labelling and machine learning platform. Delivers results in under 5 minutes with 99% accuracy from throat and nose swab samples. Sold to UK Ministry of Defence and allied military forces.
  • PIC-ID Capture (consumable reagent cartridges) Proprietary single universal fluorescent labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. One reagent serves all tests, simplifying inventory versus pathogen-specific primers. Sold as a consumable alongside the VISTA Reader.

Quantifiable outcome

  • 97-98% accuracy from 155 patient samples in clinical validation
  • +5 more outcomes

Companies that use PicturaBio

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

PicturaBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

PicturaBio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • NHS PortsmouthcoreStrategic or Co-development PartnerPartnership with NHS Portsmouth Emergency Department for clinical validation of the Pictura Bio diagnostic platform. Company explicitly mentions this partnership as fundamental to overcoming clinical adoption challenges.
  • Queen Alexandra Hospital (Portsmouth)coreStrategic or Co-development PartnerClinical trial partner for Novel Technologies for Respiratory Virus Identification (ResVir) study registered as NCT05661032. First large-scale sample collection initiative generating respiratory pathogen dataset for PIC-ID Identify machine learning training.
  • John Radcliffe HospitalcoreStrategic or Co-development PartnerCollaborated with John Radcliffe Hospital to evaluate the diagnostic method using AI software to identify viruses. Over 200 clinical samples were labelled and analysed, demonstrating >97% accuracy in identifying respiratory viruses.
  • University of OxfordcoreStrategic or Co-development PartnerPictura Bio is a spinout from the University of Oxford. Scientific co-founders Nicolas Shiaelis and Dr. Nicole Robb originated from Oxford. Company maintains connection with Oxford's emerging viruses research group led by Professor Miles Carroll.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

PicturaBio competitors and assessment

Company assessment

Direct peers

  • QuantuMDx: QuantuMDx is a UK-based developer of the Q-POC rapid molecular POC platform. As a similarly-sized UK diagnostics challenger targeting decentralized infectious disease and antimicrobial resistance testing, it is closely comparable in stage and go-to-market motion.
  • Qiagen: Qiagen's QIAstat-Dx is a syndromic molecular diagnostic platform for respiratory and gastrointestinal infections, directly comparable to PicturaBio's multiplex POC positioning. Both target hospital labs and EDs with rapid, panel-based detection.
  • bioMérieux: bioMérieux's BioFire FilmArray is the dominant multiplex syndromic molecular panel for rapid infectious disease diagnostics in hospitals, targeting the same ED/ICU customer segment as PicturaBio's VISTA. Both platforms deliver rapid, sample-to-answer multiplex pathogen identification from a single sample.
  • Cepheid (Danaher): Cepheid's GeneXpert is the market-leading rapid molecular point-of-care platform for infectious disease (TB, CT/NG, respiratory viruses, SARS-CoV-2). It competes head-to-head with PicturaBio on turnaround time and decentralization for hospitals and clinics.
  • T2 Biosystems: T2 Biosystems uses T2 Magnetic Resonance to detect pathogens (T2Candida, T2Bacteria) directly from whole blood without culture. It is a direct peer in rapid, culture-independent pathogen identification at the hospital bedside.
  • Binx Health: Binx Health's io system is a rapid molecular POC platform initially deployed for CT/NG testing at pharmacies, clinics and EDs - directly comparable in targeting decentralized clinical settings with rapid sample-to-answer molecular diagnostics.

Emerging players

  • Accelerate Diagnostics: Accelerate Diagnostics' Pheno system provides rapid ID and AST directly from positive blood cultures. It competes in the same rapid-pathogen-identification workflow that PicturaBio's universal-labelling / AI approach ultimately aims to address.
  • Specific Diagnostics: Specific Diagnostics develops a rapid phenotypic ID/AST platform using biochemical sensors, targeting bloodstream infection identification and antibiotic susceptibility within hours. It is an emerging peer in the rapid phenotypic pathogen identification space where PicturaBio also competes.
  • Oxford Nanopore Technologies: Oxford Nanopore's sequencing-based platform is being adopted for rapid infectious disease surveillance and outbreak response. It is an adjacent, emerging technology converging on rapid decentralized pathogen identification - though via sequencing rather than imaging/AI.

Broad incumbents

  • Bruker: Bruker's MALDI Biotyper is a widely deployed rapid microbial identification platform using mass spectrometry in clinical microbiology labs. As a broad incumbent in microbial ID, it competes for the same hospital-lab budget that PicturaBio's VISTA targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PicturaBio social profiles

Digital presence

PicturaBio compliance and trust

Trust signal

Compliance1 record

PicturaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PicturaBio leadership team

Management profile

Number of profiles

Profiles13 records

PicturaBio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PicturaBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PicturaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PicturaBio

What does PicturaBio do?

Pictura Bio develops and is commercialising a one-minute infectious disease pathogen detection platform combining a proprietary universal fluorescent labelling reagent (PIC-ID Capture), a benchtop fluorescence microscopy instrument (VISTA Reader), and a deep learning image analysis algorithm (PIC-ID Identify). The integrated platform is sold to hospitals, GP surgeries, pharmacies, and defence customers for point-of-care identification of respiratory viruses, bacteria, and other pathogens.

Is PicturaBio a public or private company?

PicturaBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was PicturaBio founded?

PicturaBio was founded in 2022. It employs 11 to 50 people.

Where is PicturaBio based?

PicturaBio is headquartered in Oxford, United Kingdom, in the Europe region.

How does PicturaBio make money?

Three revenue lines are on record. Diagnostic Device Sales are the primary driver. The others are software Updates and Licensing and government and Defence Contracts.

Who are PicturaBio's main competitors?

Direct peers on record are QuantuMDx, Qiagen, bioMérieux, Cepheid (Danaher), T2 Biosystems and Binx Health. Emerging players are Accelerate Diagnostics, Specific Diagnostics and Oxford Nanopore Technologies. Bruker is listed as a broad incumbent.

Does PicturaBio have an API?

No public API is recorded for PicturaBio.

What industry is PicturaBio in?

PicturaBio's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAHABAL, Portable, Mobile & Point-of-Care Imaging Systems. Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales